Fostering orphan receptors: An indispensable role for integrative in vivo, haemodynamic studies

Current Opinion in Pharmacology

Volumn 3, Issue 2, 2003, Pages 140-145

  Bennett, Terence ^a   Gardiner, Sheila M ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; ADRENOMEDULLIN; ANANDAMIDE; ANESTHETIC AGENT; ARGININEPHENYLALANINE; ARGININETRYPTOPHAN; ATENOLOL; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; DRUG RECEPTOR; G PROTEIN COUPLED RECEPTOR; GHRELIN; LIGAND; MOTILIN; NEUROKININ B; NEUROMEDIN B; NEUROMEDIN C; NEUROMEDIN N; NEUROMEDIN U 23; NEUROMEDIN U 25; NEUROMEDIN U 8; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR; NEUROTENSIN; PHENTOLAMINE; PHENYLALANINE METHIONINEARGININEPHENYLALANINEAMIDE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROTENSIN II; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANESTHESIA INDUCTION; ARTERIAL PRESSURE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR EFFECT; CARDIOVASCULAR SYSTEM; DOSE RESPONSE; DRUG RECEPTOR BINDING; DRUG TARGETING; GENOTYPE PHENOTYPE CORRELATION; HEART RATE; HEMODYNAMICS; IN VITRO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; RELIABILITY; REVIEW;

ANIMALS; HEMODYNAMIC PROCESSES; HUMANS; LIGANDS; RECEPTORS, CELL SURFACE;

EID: 0037385670     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(03)00004-3     Document Type: Review

References (45)

1. Katugampola SD, Maguire JJ, Kuc RE, Wiley KE, Davenport AP: Discovery of recently adopted orphan receptors for apelin, urotensin II, and ghrelin identified using novel radioligands and functional role in the human cardiovascular system. Can J Physiol Pharmacol 2002, 80:369-374.
2. Kenakin T: Recombinant roulette versus the apparent virtues of 'natural' cell receptor systems: receptor genotypes versus phenotypes. Trends Pharmacol Sci 2002, 23:403-404.
3. Szekeres PG, Muir AL, Spinage LD, Miller JE, Butler SI, Smith A, Renniel GI, Murdock PR, Fitzgerald LR, Hsiao-ling W et al.: Neuromedin U is a potent agonist at the orphan G-protein-coupled receptor FM3. J Biol Chem 2000, 275:20247-20250.
4. Fujii R, Hosoya M, Fukusumi S, Kawamata Y, Habata Y, Hinuma S, Onda H, Nishimura O, Fujino M: Identification of neuromedin U as the cognate ligand of the orphan G-protein-coupled receptor FM-3. J Biol Chem 2000, 275:21068-21074.
5. Howard AD, Wang R, Pong SS, Mellin TN, Strack A, Guan XM, Zeng Z, Williams DL, Feighner SD, Nunes CN et al.: Identification of receptors for neuromedin U and its role in feeding. Nature 2000, 406:70-74.
6. Kojima M, Haruno R, Nakazato M, Date Y, Murakami N, Hanada R. Matsuo H, Kangawa K: Purification and identification of neuromedin U as an endogenous ligand for an orphan receptor GPR66 (FM3). Biochem Biophys Res Commun 2000, 276:435-438.
7. Hosoya M, Moriya T, Kawamata Y, Ohkubo S, Fujii R, Matsui H, Shintani Y, Fukusumi S, Habata Y, Hinuma S et al.: Identification and functional characterization of a novel subtype of neuromedin U receptor. J Biol Chem 2000, 275:29528-29532.
8. Gardiner SM, Compton AM, Bennett T, Domin J, Bloom SR: Regional hemodynamic effects of neuromedin U in conscious rats. Am J Physiol 1990, 258:R32-R38.
9. + channel. J Biol Chem 1996, 271:7879-7882.
10. Clements MK, McDonald TP, Wang R, Xie G, O'Dowd BF, George SR, Austin CP, Liu Q: FMRFamide-related neuropeptides are agonists of the orphan G-protein-coupled receptor GPR54. Biochem Biophys Res Commun 2001, 284:1189-1193.
11. Thiemermann C, Al-Damluji S, Hecker M, Vane JR: FMRFamide and L-Arg-L-Phe increase blood pressure and heart rate in the anaesthetised rat by central stimulation of the sympathetic nervous system. Biochem Biophys Res Commun 1991, 175:318-324.
12. Nishimura M, Ohtsuka K, Takahashi H, Yoshimura M: Role of FMRFamide-activated brain sodium channel in salt-sensitive hypertension. Hypertension 2000, 35(Suppl):443-450.
13. Widdop RE, Gardiner SM, Kemp PA, Bennett T: Cardiac haemodynamic effects of L-arginyl-L-phenylalanine in conscious rats [abstract]. Br J Pharmacol 1991, 104:122P.
14. Parker SL, Parker MS: FMRFamides exert a unique modulation of rodent pancreatic polypeptide sensitive neuropeptide Y (NPY) receptors. Can J Physiol Pharmacol 2000, 78:150-161.
15. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW et al.: Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999, 401:282-286.
16. Elshourbagy NA, Douglas SA, Shabon U, Harrison S, Duddy G, Sechler JL, Ao Z, Malceff BE, Naselsky D, Disa J, Aiyar NV: Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br J Pharmacol 2002, 136:9-22.
17. Russell FD, Molenaar P, O'Brien DM: Cardiostimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol 2001, 132:5-9.
18. Gardiner SM, March JE, Kemp PA, Davenport AP, Bennett T: Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats. Br J Pharmacol 2001, 132:1625-1629.
19. Bennett T, March JE, Kemp PA, Gardiner SM: Regional haemodynamic responses to infusion of human urotensin II (hUII) in conscious Sprague-Dawley rats [abstract]. Br J Pharmacol 2002, 135:200P.
20. Wilkinson IB, Affolter JT, de Haas SL, Pellegrini MP, Boyd J, Winter MJ, Balment RJ, Webb DJ: High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc Res 2002, 53:341-347.
21. Böhm F, Pernow J: Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol 2002, 135:25-27.
22. Conlon JM: Singular contributions of fish neuroendocrinology to mammalian regulatory peptide research. Regul Pept 2000, 93:3-12.
23. Bennett T, March JE, Kemp PA, Gardiner SM: Cardiovascular effects of corticotropin releasing factor (CRF) compared with human urotensin II (h-UII) in conscious rats [abstract]. Br J Pharmacol 2002, 135:38P.
24. May C, Parkes D: Cardiovascular actions of urocortin are independent of the sympathetic nervous system [abstract]. J Hypertens 2000, 18:P301.
25. Rosen ED, Spiegelman BM: PPARγ: a nuclear regulator of metabolism, differentiation and cell growth. J Biol Chem 2001, 276:37731-37734.
26. Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med 2002, 53:409-435.
27. Willson TM, Brown PJ, Sternbach DD, Henke BR: The PPARs: from orphan receptors to drug discovery. J Med Chem 2000, 43:527-550.
28. Gardiner SM, Kemp PA, March JE, Baer PG, Brown KK, Nunez D, Bennett T: Regional haemodynamic effects of the PPARγ activator, GI 262570, in conscious rats [abstract]. Br J Pharmacol 2002, 137:29P.
29. Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, Muff R, Fischer JA, Foord SM: International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin and calcitonin receptors. Pharmacol Rev 2002, 54:233-246.
30. Nuki C, Kawasaki H, Kitamura K, Takenaga M, Kangawa K, Eto T, Wada A: Vasodilator effect of adrenomedullin and calcitonin gene-related peptide receptors in rat mesenteric vascular beds. Biochem Biophys Res Commun 1993, 196:245-251.
31. Gardiner SM, Kemp PA, March JE, Bennett T: Regional haemodynamic effects of human and rat adrenomedullin in conscious rats. Br J Pharmacol 1995, 114:584-591.
32. Gardiner SM, Compton AM, Kemp PA, Bennett T, Bose C, Foulkes R, Hughes B: Antagonistic effect of human α-calcitonin gene-related peptide (8-37) on regional hemodynamic actions of rat islet amyloid polypeptide in conscious Long-Evans rats. Diabetes 1991, 40:948-951.
33. Swanson GN, Hanesworth JM, Sardinia MF, Coleman JKM, Wright JW, Hall KL, Miller-Wing AV, Stobb JW, Cook VI, Harding EC, Harding JW: Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptor. Regul Pept 1992, 40:409-419.
34. 1 receptors. J Biol Chem 2002, 277:23107-23110.
35. Gardiner SM, Kemp PA, March JE, Bennett T: Regional haemodynamic effects of angiotensin II (3-8) in conscious rats. Br J Pharmacol 1993, 110:159-162.
36. Albiston AL, McDowall SG, Matsacos D, Sim P, Clune E, Mustafa T, Lee J, Mendelsohn FAO, Simpson RJ, Connolly LM, Chai SY: Evidence that the angiotensin IV (AT4) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem 2002, 276:48623-48626.
37. Fitzgerald SM, Evans RG, Bergström G, Anderson WP: Renal hemodynamic responses to intrarenal infusion of ligands for the putative angiotensin IV receptor in anesthetized rats. J Cardiovasc Pharmacol 1999, 34:206-211.
38. Pertwee RG, Ross RG: Cannabinoid receptors and their ligands. Prost Leuk Essent Fatty Acids 2002, 66:101-121.
39. Randall MD, Harris D, Kendall DA, Ralevic V: Cardiovascular effects of cannabinoids. Pharmacol Therap 2002, 95:191-202.
40. Martin BR: Identification of the endogenous cannabinoid system through integrative pharmacological approaches. J Pharmacol Exp Therap 2002, 301:790-796.
41. Gardiner SM, March JE, Kemp PA, Bennett T: Complex regional haemodynamic effects of anandamide in conscious rats. Br J Pharmacol 2002, 135:1889-1896.
42. 1 receptor antagonist, AM 251, on the regional haemodynamic effects of WIN-55212-2 or HU 210 in conscious rats. Br J Pharmacol 2002, 136:581-587.
43. White R, Ho W-SV, Bottrill FE, Ford WR, Hiley CR: Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries. Br J Pharmacol 2001, 134:921-929.
44. 1 receptor-mediated changes in heart rate and blood pressure in anaesthetized rats. Arch Pharmacol 2001, 364:562-569.
45. Andersson DA, Adner M, Hog̈estä tt ED, Zygmunt PM: Mechanisms underlying tissue selectivity of anandamide and other vanilloid receptor agonists. Mol Pharmacol 2002, 62:705-713.